The usefulness of cytogenetic biomarkers as intermediate endpoints in carcinogenesis
✍ Scribed by Lars Hagmar; Ulf Strömberg; Håkan Tinnerberg; Zoli Mikoczy
- Book ID
- 114494558
- Publisher
- Elsevier Science
- Year
- 2001
- Tongue
- German
- Weight
- 62 KB
- Volume
- 204
- Category
- Article
- ISSN
- 1438-4639
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
The use of nuclear morphometry as an intermediate endpoint biomarker is described in a Phase I, dose-seeking trial of chemoprevention of cervical cancer, using the agent ␣-difluoromethylornithine (DFMO). Thirty patients with grade III cervical intraepithelial neoplasia (CIN III) were enrolled, and t
The use of oncogene proteins as biomarkers offers a new approach to the molecular epidemiologic evaluation of occupational carcinogenesis. The ras oncogene-encoded p21 protein represents a prototype for this type of study, since it is known to be activated by common occupational carcinogens, is freq
Using an intermediate marker of precancer as an endpoint for evaluating agents that may prevent cancer involves a presumption that the modification of the marker will be accompanied by a modification of cancer incidence. This presumption can hold only if the marker is on or very closely linked to a